FI63938C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara substituerade 2,3-alkylenbis(oxi)bensamider - Google Patents
Foerfarande foer framstaellning av nya terapeutiskt anvaendbara substituerade 2,3-alkylenbis(oxi)bensamider Download PDFInfo
- Publication number
- FI63938C FI63938C FI772362A FI772362A FI63938C FI 63938 C FI63938 C FI 63938C FI 772362 A FI772362 A FI 772362A FI 772362 A FI772362 A FI 772362A FI 63938 C FI63938 C FI 63938C
- Authority
- FI
- Finland
- Prior art keywords
- benzodioxane
- alkyl
- substd
- opt
- carboxamide
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title description 2
- BJISZDCMBMQNIY-UHFFFAOYSA-N benzene Chemical compound [C-]1=CC=CC=C1 BJISZDCMBMQNIY-UHFFFAOYSA-N 0.000 title 1
- -1 cycloalkenylalkyl Chemical group 0.000 claims abstract description 33
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 19
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 10
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims abstract description 6
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 5
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 5
- 150000002367 halogens Chemical class 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 9
- 229940054066 benzamide antipsychotics Drugs 0.000 claims description 8
- 150000003936 benzamides Chemical class 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 31
- 239000002253 acid Substances 0.000 abstract description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 7
- 230000002903 catalepsic effect Effects 0.000 abstract description 6
- VCLSWKVAHAJSFL-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound O1CCOC2=C1C=CC=C2C(=O)O VCLSWKVAHAJSFL-UHFFFAOYSA-N 0.000 abstract description 5
- 230000003474 anti-emetic effect Effects 0.000 abstract description 3
- 239000002249 anxiolytic agent Substances 0.000 abstract description 3
- 230000000949 anxiolytic effect Effects 0.000 abstract description 3
- 150000003839 salts Chemical class 0.000 abstract description 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000000304 alkynyl group Chemical group 0.000 abstract 5
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 4
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 3
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 3
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 125000003441 thioacyl group Chemical group 0.000 abstract 2
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 abstract 1
- 150000003863 ammonium salts Chemical class 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 abstract 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 96
- 239000000243 solution Substances 0.000 description 86
- 239000000203 mixture Substances 0.000 description 81
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 71
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 60
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 54
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 239000002244 precipitate Substances 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- 239000013078 crystal Substances 0.000 description 30
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 28
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000002585 base Substances 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 229910021529 ammonia Inorganic materials 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- UNRBEYYLYRXYCG-UHFFFAOYSA-N (1-ethylpyrrolidin-2-yl)methanamine Chemical compound CCN1CCCC1CN UNRBEYYLYRXYCG-UHFFFAOYSA-N 0.000 description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 11
- 238000001953 recrystallisation Methods 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- JUFKJRCMBLLXNH-UHFFFAOYSA-N (1-methylpyrrolidin-2-yl)methanamine Chemical compound CN1CCCC1CN JUFKJRCMBLLXNH-UHFFFAOYSA-N 0.000 description 7
- RKSFKFSIQAQPHQ-UHFFFAOYSA-N 7-(methylsulfamoyl)-2,3-dihydro-1,4-benzodioxine-5-carbonyl chloride Chemical compound O1CCOC2=C1C=C(S(=O)(=O)NC)C=C2C(Cl)=O RKSFKFSIQAQPHQ-UHFFFAOYSA-N 0.000 description 7
- AJEDNQSLTXJFJG-UHFFFAOYSA-N 7-ethylsulfonyl-2,3-dihydro-1,4-benzodioxine-5-carbonyl chloride Chemical compound O1CCOC2=C1C=C(S(=O)(=O)CC)C=C2C(Cl)=O AJEDNQSLTXJFJG-UHFFFAOYSA-N 0.000 description 7
- HTGKTSVPJJNEMQ-QMMMGPOBSA-N [(2s)-1-prop-2-enylpyrrolidin-2-yl]methanamine Chemical compound NC[C@@H]1CCCN1CC=C HTGKTSVPJJNEMQ-QMMMGPOBSA-N 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- YRXDDQLZROFCKK-UHFFFAOYSA-N n-[(1-ethylpyrrolidin-2-yl)methyl]-7-ethylsulfonyl-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=CC2=C1OCCO2 YRXDDQLZROFCKK-UHFFFAOYSA-N 0.000 description 7
- POVZSJGKGZYZPS-UHFFFAOYSA-N n-[(1-methylpyrrolidin-2-yl)methyl]-7-(methylsulfamoyl)-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound C=1C(S(=O)(=O)NC)=CC=2OCCOC=2C=1C(=O)NCC1CCCN1C POVZSJGKGZYZPS-UHFFFAOYSA-N 0.000 description 7
- NCSFGFOXYGSSSH-UHFFFAOYSA-N 7-chlorosulfonyl-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound O1CCOC2=C1C=C(S(Cl)(=O)=O)C=C2C(=O)O NCSFGFOXYGSSSH-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 150000003857 carboxamides Chemical class 0.000 description 6
- KHDSNFILCIVZDT-UHFFFAOYSA-N n-[(1-ethylpyrrolidin-2-yl)methyl]-7-(methylsulfamoyl)-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)NC)=CC2=C1OCCO2 KHDSNFILCIVZDT-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- SXAKAOFKGIOPHK-UHFFFAOYSA-N methyl 7-sulfamoyl-2,3-dihydro-1,4-benzodioxine-5-carboxylate Chemical compound O1CCOC2=C1C=C(S(N)(=O)=O)C=C2C(=O)OC SXAKAOFKGIOPHK-UHFFFAOYSA-N 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- LKYLYFSTNNVQNS-UHFFFAOYSA-N 5-amino-2,3-dihydro-1,4-benzodioxine-8-carboxylic acid Chemical compound O1CCOC2=C1C(C(O)=O)=CC=C2N LKYLYFSTNNVQNS-UHFFFAOYSA-N 0.000 description 4
- XOPARDXSIMENIK-UHFFFAOYSA-N 7-(dimethylsulfamoyl)-2,3-dihydro-1,4-benzodioxine-5-carbonyl chloride Chemical compound O1CCOC2=C1C=C(S(=O)(=O)N(C)C)C=C2C(Cl)=O XOPARDXSIMENIK-UHFFFAOYSA-N 0.000 description 4
- ZHWMIKHMSOYRBC-UHFFFAOYSA-N 7-ethylsulfonyl-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound O1CCOC2=C1C=C(S(=O)(=O)CC)C=C2C(O)=O ZHWMIKHMSOYRBC-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- UAMRSLPXDICKQF-UHFFFAOYSA-N methyl 7-(methylsulfamoyl)-2,3-dihydro-1,4-benzodioxine-5-carboxylate Chemical compound O1CCOC2=C1C=C(S(=O)(=O)NC)C=C2C(=O)OC UAMRSLPXDICKQF-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 231100000957 no side effect Toxicity 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 3
- IEWVBBWTJOHHCY-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-5-carbonyl chloride Chemical compound O1CCOC2=C1C=CC=C2C(=O)Cl IEWVBBWTJOHHCY-UHFFFAOYSA-N 0.000 description 3
- QYLUBOYUQYTVSP-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1,4-benzodioxine-8-carbonyl chloride Chemical compound O1CCOC2=C1C(C(Cl)=O)=CC=C2OC QYLUBOYUQYTVSP-UHFFFAOYSA-N 0.000 description 3
- PWJRPWPPVFPUQD-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1,4-benzodioxine-8-carboxylic acid Chemical compound O1CCOC2=C1C(C(O)=O)=CC=C2OC PWJRPWPPVFPUQD-UHFFFAOYSA-N 0.000 description 3
- SJKOZUVHRPRMRJ-UHFFFAOYSA-N 6,7-dibromo-5-nitro-2,3-dihydro-1,4-benzodioxine-8-carbonyl chloride Chemical compound O1CCOC2=C1C(C(Cl)=O)=C(Br)C(Br)=C2[N+](=O)[O-] SJKOZUVHRPRMRJ-UHFFFAOYSA-N 0.000 description 3
- JTKAQKREMDVCLQ-UHFFFAOYSA-N 7-(dimethylsulfamoyl)-n-[(1-methylpyrrolidin-2-yl)methyl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound C=1C(S(=O)(=O)N(C)C)=CC=2OCCOC=2C=1C(=O)NCC1CCCN1C JTKAQKREMDVCLQ-UHFFFAOYSA-N 0.000 description 3
- RNNLXFYGDGETIY-UHFFFAOYSA-N 7-ethylsulfanyl-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound O1CCOC2=C1C=C(SCC)C=C2C(O)=O RNNLXFYGDGETIY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- NVNRWKTVXWAHHF-UHFFFAOYSA-N methyl 5-methoxy-6-sulfamoyl-2,3-dihydro-1,4-benzodioxine-8-carboxylate Chemical compound O1CCOC2=C1C(OC)=C(S(N)(=O)=O)C=C2C(=O)OC NVNRWKTVXWAHHF-UHFFFAOYSA-N 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- OEYAFMGVIFWPQI-UHFFFAOYSA-N (1-benzylpyrrolidin-2-yl)methanamine Chemical compound NCC1CCCN1CC1=CC=CC=C1 OEYAFMGVIFWPQI-UHFFFAOYSA-N 0.000 description 2
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- LYCFLVALOZTFDX-UHFFFAOYSA-N 5-acetamido-2,3-dihydro-1,4-benzodioxine-8-carboxylic acid Chemical compound O1CCOC2=C1C(C(O)=O)=CC=C2NC(=O)C LYCFLVALOZTFDX-UHFFFAOYSA-N 0.000 description 2
- ZTAULNSGZBLXPD-UHFFFAOYSA-N 5-acetamido-2,3-dihydro-1,4-benzodioxine-8-carboxylic acid 5-acetamido-N-[(1-ethylpyrrolidin-2-yl)methyl]-2,3-dihydro-1,4-benzodioxine-8-carboxamide Chemical compound N(C(=O)C)C1=CC=C(C2=C1OCCO2)C(=O)O.C(C)N2C(CCC2)CNC(=O)C2=CC=C(C=1OCCOC12)NC(=O)C ZTAULNSGZBLXPD-UHFFFAOYSA-N 0.000 description 2
- DAZVOZDOZMSYIL-UHFFFAOYSA-N 5-methoxy-6-sulfamoyl-2,3-dihydro-1,4-benzodioxine-8-carboxylic acid Chemical compound O1CCOC2=C(C(O)=O)C=C(S(N)(=O)=O)C(OC)=C21 DAZVOZDOZMSYIL-UHFFFAOYSA-N 0.000 description 2
- YAQJEXMCCBHATG-UHFFFAOYSA-N 6,7-dibromo-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound O1CCOC2=C1C=C(Br)C(Br)=C2C(=O)O YAQJEXMCCBHATG-UHFFFAOYSA-N 0.000 description 2
- HAQXDCQBSQSHSQ-UHFFFAOYSA-N 6,7-dibromo-n-[(1-ethylpyrrolidin-2-yl)methyl]-5-nitro-2,3-dihydro-1,4-benzodioxine-8-carboxamide Chemical compound CCN1CCCC1CNC(=O)C1=C(Br)C(Br)=C([N+]([O-])=O)C2=C1OCCO2 HAQXDCQBSQSHSQ-UHFFFAOYSA-N 0.000 description 2
- QFTQYWNNATXJGG-UHFFFAOYSA-N 6-chlorosulfonyl-5-methoxy-2,3-dihydro-1,4-benzodioxine-8-carboxylic acid Chemical compound O1CCOC2=C(C(O)=O)C=C(S(Cl)(=O)=O)C(OC)=C21 QFTQYWNNATXJGG-UHFFFAOYSA-N 0.000 description 2
- MVYGNUFUGOZHQE-UHFFFAOYSA-N 66411-18-5 Chemical compound O1CCOC2=C1C([N+]([O-])=O)=C(Br)C(Br)=C2C(=O)O MVYGNUFUGOZHQE-UHFFFAOYSA-N 0.000 description 2
- CJPGSUPNJOCTCY-UHFFFAOYSA-N 7-(diethylsulfamoyl)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound O1CCOC2=C1C=C(S(=O)(=O)N(CC)CC)C=C2C(O)=O CJPGSUPNJOCTCY-UHFFFAOYSA-N 0.000 description 2
- ZRISRDUHJZSFSK-UHFFFAOYSA-N 7-(dimethylsulfamoyl)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound O1CCOC2=C1C=C(S(=O)(=O)N(C)C)C=C2C(O)=O ZRISRDUHJZSFSK-UHFFFAOYSA-N 0.000 description 2
- AUIYGHHLPMMOGF-UHFFFAOYSA-N 7-(dimethylsulfamoyl)-n-[(1-ethylpyrrolidin-2-yl)methyl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)N(C)C)=CC2=C1OCCO2 AUIYGHHLPMMOGF-UHFFFAOYSA-N 0.000 description 2
- NQEQVGJQJCYZNI-UHFFFAOYSA-N 7-(methylsulfamoyl)-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound O1CCOC2=C1C=C(S(=O)(=O)NC)C=C2C(O)=O NQEQVGJQJCYZNI-UHFFFAOYSA-N 0.000 description 2
- YHFLGEVINDZKFY-UHFFFAOYSA-N 7-ethylsulfonyl-n-[(1-methylpyrrolidin-2-yl)methyl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound C=1C(S(=O)(=O)CC)=CC=2OCCOC=2C=1C(=O)NCC1CCCN1C YHFLGEVINDZKFY-UHFFFAOYSA-N 0.000 description 2
- GPKDBCCYRICYKP-UHFFFAOYSA-N 7-sulfamoyl-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound O1CCOC2=C1C=C(S(=O)(=O)N)C=C2C(O)=O GPKDBCCYRICYKP-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NPLTWXLPSQLCFW-UHFFFAOYSA-N C(C(=O)O)(=O)O.C(C(=O)O)(=O)O.C(C)N1C(CCC1)CNC(=O)C1=CC=C(C=2OCCOC21)OC Chemical compound C(C(=O)O)(=O)O.C(C(=O)O)(=O)O.C(C)N1C(CCC1)CNC(=O)C1=CC=C(C=2OCCOC21)OC NPLTWXLPSQLCFW-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- GNQRWGKVRSPWSM-UHFFFAOYSA-N n-(1-cyclohexylpyrrolidin-3-yl)-7-(methylsulfamoyl)-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound C=1C(S(=O)(=O)NC)=CC=2OCCOC=2C=1C(=O)NC(C1)CCN1C1CCCCC1 GNQRWGKVRSPWSM-UHFFFAOYSA-N 0.000 description 2
- ZYEKQMNBMUWLOB-UHFFFAOYSA-N n-[(1-benzylpyrrolidin-2-yl)methyl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.C=1C=CC=2OCCOC=2C=1C(=O)NCC1CCCN1CC1=CC=CC=C1 ZYEKQMNBMUWLOB-UHFFFAOYSA-N 0.000 description 2
- CWMGJIZXWZOWJU-UHFFFAOYSA-N n-[(1-benzylpyrrolidin-2-yl)methyl]-7-(diethylsulfamoyl)-2,3-dihydro-1,4-benzodioxine-5-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.C=1C(S(=O)(=O)N(CC)CC)=CC=2OCCOC=2C=1C(=O)NCC1CCCN1CC1=CC=CC=C1 CWMGJIZXWZOWJU-UHFFFAOYSA-N 0.000 description 2
- QAXBBRZVNDSSPG-UHFFFAOYSA-N n-[(1-ethylpyrrolidin-2-yl)methyl]-1,3-benzodioxole-4-carboxamide;hydrochloride Chemical compound Cl.CCN1CCCC1CNC(=O)C1=CC=CC2=C1OCO2 QAXBBRZVNDSSPG-UHFFFAOYSA-N 0.000 description 2
- NHROVAANFJEPPV-UHFFFAOYSA-N n-[(1-ethylpyrrolidin-2-yl)methyl]-2,3-dihydro-1,4-benzodioxine-5-carboxamide;hydrochloride Chemical compound Cl.CCN1CCCC1CNC(=O)C1=CC=CC2=C1OCCO2 NHROVAANFJEPPV-UHFFFAOYSA-N 0.000 description 2
- JYHVHIHNOSYGLA-UHFFFAOYSA-N n-[(1-ethylpyrrolidin-2-yl)methyl]-5-methoxy-2,3-dihydro-1,4-benzodioxine-8-carboxamide Chemical compound CCN1CCCC1CNC(=O)C1=CC=C(OC)C2=C1OCCO2 JYHVHIHNOSYGLA-UHFFFAOYSA-N 0.000 description 2
- PNQWQELYAPSYBA-UHFFFAOYSA-N n-[(1-ethylpyrrolidin-2-yl)methyl]-5-methoxy-6-sulfamoyl-2,3-dihydro-1,4-benzodioxine-8-carboxamide Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=C(OC)C2=C1OCCO2 PNQWQELYAPSYBA-UHFFFAOYSA-N 0.000 description 2
- LLANSHIYQPLIKH-UHFFFAOYSA-N n-[(1-ethylpyrrolidin-2-yl)methyl]-7-sulfamoyl-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC2=C1OCCO2 LLANSHIYQPLIKH-UHFFFAOYSA-N 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical class ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000003368 psychostimulant agent Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- CFGDUGSIBUXRMR-UHFFFAOYSA-N 1,2-dihydropyrrol-2-ide Chemical class C=1C=[C-]NC=1 CFGDUGSIBUXRMR-UHFFFAOYSA-N 0.000 description 1
- LVBLTFSJUMJXBI-UHFFFAOYSA-N 1,3-benzodioxole-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=CC2=C1OCO2 LVBLTFSJUMJXBI-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DPEPZAJVZHRORQ-UHFFFAOYSA-N 1-cyclohexylpyrrolidin-3-amine Chemical compound C1C(N)CCN1C1CCCCC1 DPEPZAJVZHRORQ-UHFFFAOYSA-N 0.000 description 1
- YGDRPEIHNMXLJM-UHFFFAOYSA-N 2,3-dihydroxy-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C(O)=C1O YGDRPEIHNMXLJM-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VXEGSRKPIUDPQT-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)piperazin-1-yl]aniline Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(N)=CC=2)CC1 VXEGSRKPIUDPQT-UHFFFAOYSA-N 0.000 description 1
- OZGDSSXESIMADL-UHFFFAOYSA-N 5-acetamido-6-nitro-2,3-dihydro-1,4-benzodioxine-8-carboxylic acid Chemical compound O1CCOC2=C(C(O)=O)C=C([N+]([O-])=O)C(NC(=O)C)=C21 OZGDSSXESIMADL-UHFFFAOYSA-N 0.000 description 1
- YIHVNRIFOBREPB-UHFFFAOYSA-N 5-acetamido-n-[(1-ethylpyrrolidin-2-yl)methyl]-2,3-dihydro-1,4-benzodioxine-8-carboxamide Chemical compound CCN1CCCC1CNC(=O)C1=CC=C(NC(C)=O)C2=C1OCCO2 YIHVNRIFOBREPB-UHFFFAOYSA-N 0.000 description 1
- WRIYOBWMCQYZLV-UHFFFAOYSA-N 5-amino-n-[(1-ethylpyrrolidin-2-yl)methyl]-2,3-dihydro-1,4-benzodioxine-8-carboxamide Chemical compound CCN1CCCC1CNC(=O)C1=CC=C(N)C2=C1OCCO2 WRIYOBWMCQYZLV-UHFFFAOYSA-N 0.000 description 1
- YVMFPRFSXLLATH-UHFFFAOYSA-N 5-amino-n-[(1-ethylpyrrolidin-2-yl)methyl]-2,3-dihydro-1,4-benzodioxine-8-carboxamide;dihydrochloride Chemical compound Cl.Cl.CCN1CCCC1CNC(=O)C1=CC=C(N)C2=C1OCCO2 YVMFPRFSXLLATH-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- ICGQFSSFYCENOY-UHFFFAOYSA-N 7-sulfanyl-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound O1CCOC2=C1C=C(S)C=C2C(=O)O ICGQFSSFYCENOY-UHFFFAOYSA-N 0.000 description 1
- HCXGTVQTCVPNPQ-UHFFFAOYSA-N 8-acetamido-6-nitro-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound O1CCOC2=C1C(C(O)=O)=C([N+]([O-])=O)C=C2NC(=O)C HCXGTVQTCVPNPQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DZVSDCSGXGQGCS-UHFFFAOYSA-N BrC1=C(C2=C(OCCO2)C=C1Br)C(=O)O.C(C)N1C(CCC1)CNC(=O)C1=C(C(=C(C=2OCCOC21)[N+](=O)[O-])Br)Br Chemical compound BrC1=C(C2=C(OCCO2)C=C1Br)C(=O)O.C(C)N1C(CCC1)CNC(=O)C1=C(C(=C(C=2OCCOC21)[N+](=O)[O-])Br)Br DZVSDCSGXGQGCS-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- MWQSGQNIOADCJY-UHFFFAOYSA-N C(C)N(S(=O)(=O)C=1C=C(C2=C(OCCO2)C1)C(=O)O)CC.P(=O)(O)(O)O.C(C1=CC=CC=C1)N1C(CCC1)CNC(=O)C1=CC(=CC=2OCCOC21)S(N(CC)CC)(=O)=O Chemical compound C(C)N(S(=O)(=O)C=1C=C(C2=C(OCCO2)C1)C(=O)O)CC.P(=O)(O)(O)O.C(C1=CC=CC=C1)N1C(CCC1)CNC(=O)C1=CC(=CC=2OCCOC21)S(N(CC)CC)(=O)=O MWQSGQNIOADCJY-UHFFFAOYSA-N 0.000 description 1
- ZMZNZWUQNNNHJS-UHFFFAOYSA-N C(C)N1C(CCC1)CNC(=O)CC1=CC(=CC=2OCCOC21)S(NC)(=O)=O Chemical compound C(C)N1C(CCC1)CNC(=O)CC1=CC(=CC=2OCCOC21)S(NC)(=O)=O ZMZNZWUQNNNHJS-UHFFFAOYSA-N 0.000 description 1
- APZWNSHEIHLOAW-UHFFFAOYSA-N COC1=C(C=C(C2=C1OCCO2)C(=O)O)S(=O)(=O)Cl.C(C)N2C(CCC2)CNC(=O)C2=CC(=C(C=1OCCOC12)OC)S(N)(=O)=O Chemical compound COC1=C(C=C(C2=C1OCCO2)C(=O)O)S(=O)(=O)Cl.C(C)N2C(CCC2)CNC(=O)C2=CC(=C(C=1OCCOC12)OC)S(N)(=O)=O APZWNSHEIHLOAW-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000009738 Connective Tissue Neoplasms Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- JXRRWBSRLJIIBC-UHFFFAOYSA-N N-[(1-ethylpyrrolidin-2-yl)methyl]-7-sulfamoyl-2,3-dihydro-1,4-benzodioxine-5-carboxamide 7-sulfamoyl-2,3-dihydro-1,4-benzodioxine-5-carboxylic acid Chemical compound S(N)(=O)(=O)C=1C=C(C2=C(OCCO2)C1)C(=O)O.C(C)N1C(CCC1)CNC(=O)C1=CC(=CC=2OCCOC21)S(N)(=O)=O JXRRWBSRLJIIBC-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- MOMWFXLCFJOAFX-UHFFFAOYSA-N OOOOOOOO Chemical compound OOOOOOOO MOMWFXLCFJOAFX-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- VKBJLTSJJWJIAX-UHFFFAOYSA-N SC=1C=C(C2=C(OCCO2)C1)C(=O)O.CN1C(CCC1)CNC(=O)C1=CC(=CC=2OCCOC21)S(=O)(=O)CC Chemical compound SC=1C=C(C2=C(OCCO2)C1)C(=O)O.CN1C(CCC1)CNC(=O)C1=CC(=CC=2OCCOC21)S(=O)(=O)CC VKBJLTSJJWJIAX-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- DQTRYXANLKJLPK-UHFFFAOYSA-N chlorophosphonous acid Chemical class OP(O)Cl DQTRYXANLKJLPK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- TYQKHCZKVCIXAJ-UHFFFAOYSA-N ethyl 1,3-benzodioxole-4-carboxylate Chemical compound CCOC(=O)C1=CC=CC2=C1OCO2 TYQKHCZKVCIXAJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-M ethyl sulfate Chemical compound CCOS([O-])(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-M 0.000 description 1
- WMYNMYVRWWCRPS-UHFFFAOYSA-N ethynoxyethane Chemical group CCOC#C WMYNMYVRWWCRPS-UHFFFAOYSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 244000145841 kine Species 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- DOAJWTSNTNAEIY-UHFFFAOYSA-N methyl 2,3-dihydroxybenzoate Chemical compound COC(=O)C1=CC=CC(O)=C1O DOAJWTSNTNAEIY-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- OSHBWNDEMSQXLY-UHFFFAOYSA-N n-[(1-ethylpyrrolidin-2-yl)methyl]-1,3-benzodioxole-4-carboxamide Chemical compound CCN1CCCC1CNC(=O)C1=CC=CC2=C1OCO2 OSHBWNDEMSQXLY-UHFFFAOYSA-N 0.000 description 1
- NFQKESSYOQXCKS-UHFFFAOYSA-N n-[(1-ethylpyrrolidin-2-yl)methyl]-7-ethylsulfonyl-2,3-dihydro-1,4-benzodioxine-5-carboxamide;hydrochloride Chemical compound Cl.CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=CC2=C1OCCO2 NFQKESSYOQXCKS-UHFFFAOYSA-N 0.000 description 1
- LVYXPIJZDUZGKR-UHFFFAOYSA-N n-[(1-methylpyrrolidin-2-yl)methyl]-7-sulfamoyl-2,3-dihydro-1,4-benzodioxine-5-carboxamide Chemical compound CN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC2=C1OCCO2 LVYXPIJZDUZGKR-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000005049 silicon tetrachloride Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001519 thymoleptic effect Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/02—Seven-membered rings
- C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7623835 | 1976-08-04 | ||
| FR7623835A FR2360305A1 (fr) | 1976-08-04 | 1976-08-04 | Nouveaux 2,3-alkylene bis (oxy)benzamides substitues, leurs derives et leurs procedes de preparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI772362A FI772362A (da) | 1978-02-05 |
| FI63938B FI63938B (fi) | 1983-05-31 |
| FI63938C true FI63938C (fi) | 1983-09-12 |
Family
ID=9176558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI772362A FI63938C (fi) | 1976-08-04 | 1977-08-04 | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara substituerade 2,3-alkylenbis(oxi)bensamider |
Country Status (37)
| Country | Link |
|---|---|
| JP (1) | JPS57167914A (da) |
| AR (1) | AR219709A1 (da) |
| AT (1) | AT358034B (da) |
| AU (1) | AU516033B2 (da) |
| BE (1) | BE857350A (da) |
| BG (1) | BG36496A3 (da) |
| CA (1) | CA1114371A (da) |
| CH (1) | CH629198A5 (da) |
| CS (1) | CS216246B2 (da) |
| DD (1) | DD133237A5 (da) |
| DE (1) | DE2760414C2 (da) |
| DK (1) | DK152366C (da) |
| EG (1) | EG12716A (da) |
| ES (1) | ES461175A1 (da) |
| FI (1) | FI63938C (da) |
| GR (1) | GR61351B (da) |
| HK (2) | HK40382A (da) |
| HU (1) | HU179064B (da) |
| IE (2) | IE45646B1 (da) |
| IL (2) | IL52644A0 (da) |
| IN (1) | IN145473B (da) |
| LU (1) | LU77897A1 (da) |
| MC (1) | MC1154A1 (da) |
| MW (1) | MW2077A1 (da) |
| NL (1) | NL172063C (da) |
| NO (1) | NO152133C (da) |
| NZ (1) | NZ184816A (da) |
| OA (1) | OA05728A (da) |
| PH (3) | PH22114A (da) |
| PL (1) | PL111071B1 (da) |
| PT (1) | PT66865B (da) |
| RO (1) | RO72963A (da) |
| SE (2) | SE440776B (da) |
| SU (1) | SU716523A3 (da) |
| YU (1) | YU40005B (da) |
| ZA (1) | ZA774701B (da) |
| ZM (1) | ZM6077A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9027098D0 (en) * | 1990-12-13 | 1991-02-06 | Beecham Group Plc | Pharmaceuticals |
| US10083697B2 (en) | 2015-05-27 | 2018-09-25 | Google Llc | Local persisting of data for selectively offline capable voice action in a voice-enabled electronic device |
| JP6452575B2 (ja) * | 2015-08-19 | 2019-01-16 | 株式会社トクヤマ | ミルタザピンの製造方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1473829A (fr) * | 1964-06-09 | 1967-03-24 | Ile De France | Nu-(tertiaire-aminoalkyl)-méthylène dioxybenzamides et leur préparation |
-
1977
- 1977-07-11 MC MC771250A patent/MC1154A1/xx unknown
- 1977-07-29 PT PT6686577A patent/PT66865B/pt unknown
- 1977-07-29 ES ES461175A patent/ES461175A1/es not_active Expired
- 1977-07-29 BG BG037047A patent/BG36496A3/xx unknown
- 1977-07-29 IN IN1165/CAL/77A patent/IN145473B/en unknown
- 1977-07-29 DE DE19772760414 patent/DE2760414C2/de not_active Expired - Fee Related
- 1977-07-29 GR GR54066A patent/GR61351B/el unknown
- 1977-08-01 YU YU188277A patent/YU40005B/xx unknown
- 1977-08-01 BE BE1008313A patent/BE857350A/xx not_active IP Right Cessation
- 1977-08-01 OA OA56243A patent/OA05728A/xx unknown
- 1977-08-01 AU AU27507/77A patent/AU516033B2/en not_active Expired
- 1977-08-02 RO RO9124577A patent/RO72963A/ro unknown
- 1977-08-02 EG EG45577A patent/EG12716A/xx active
- 1977-08-02 LU LU77897A patent/LU77897A1/xx unknown
- 1977-08-02 IE IE1600/77A patent/IE45646B1/en not_active IP Right Cessation
- 1977-08-02 AT AT569677A patent/AT358034B/de not_active IP Right Cessation
- 1977-08-02 IE IE2409/80A patent/IE45647B1/en not_active IP Right Cessation
- 1977-08-03 MW MW2077A patent/MW2077A1/xx unknown
- 1977-08-03 SE SE7708849A patent/SE440776B/xx not_active IP Right Cessation
- 1977-08-03 NO NO772739A patent/NO152133C/no unknown
- 1977-08-03 CH CH956277A patent/CH629198A5/fr not_active IP Right Cessation
- 1977-08-03 HU HUSO001195 patent/HU179064B/hu not_active IP Right Cessation
- 1977-08-03 DK DK346977A patent/DK152366C/da not_active IP Right Cessation
- 1977-08-03 IL IL52644A patent/IL52644A0/xx not_active IP Right Cessation
- 1977-08-03 DD DD20042077A patent/DD133237A5/xx not_active IP Right Cessation
- 1977-08-03 ZA ZA00774701A patent/ZA774701B/xx unknown
- 1977-08-03 CA CA283,994A patent/CA1114371A/en not_active Expired
- 1977-08-03 NZ NZ18481677A patent/NZ184816A/xx unknown
- 1977-08-03 NL NL7708616A patent/NL172063C/xx not_active IP Right Cessation
- 1977-08-04 CS CS775179A patent/CS216246B2/cs unknown
- 1977-08-04 ZM ZM6077A patent/ZM6077A1/xx unknown
- 1977-08-04 PH PH20078A patent/PH22114A/en unknown
- 1977-08-04 FI FI772362A patent/FI63938C/fi not_active IP Right Cessation
- 1977-08-04 SU SU772507701A patent/SU716523A3/ru active
- 1977-08-04 PL PL1977200066A patent/PL111071B1/pl not_active IP Right Cessation
- 1977-08-08 AR AR26867377A patent/AR219709A1/es active
-
1981
- 1981-03-25 PH PH25426-AA patent/PH18629A/en unknown
- 1981-08-07 PH PH26025A patent/PH17710A/en unknown
-
1982
- 1982-03-19 JP JP4547682A patent/JPS57167914A/ja active Granted
- 1982-06-25 IL IL66138A patent/IL66138A0/xx not_active IP Right Cessation
- 1982-09-16 HK HK40382A patent/HK40382A/xx unknown
- 1982-09-16 HK HK40482A patent/HK40482A/xx unknown
- 1982-11-17 SE SE8206546A patent/SE453390B/sv not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5032617A (en) | Substituted benzamide radiosensitizers | |
| US5041653A (en) | Substituted benzamide radiosensitizers | |
| SU820659A3 (ru) | Способ получени производных 4-амино- 5-АлКилСульфОНилОАНизАМидОВ, иХ СОлЕй,ОКиСЕй, лЕВО- и пРАВОВРАщАющиХизОМЕРОВ /иХ ВАРиАНТы/ | |
| US4400394A (en) | Benzylidene derivatives | |
| JPS60193998A (ja) | アデノシン誘導体及び該誘導体を含有する抗アレルギー剤 | |
| FR2823209A1 (fr) | Nouvelles thiohydantoines et leur utilisation en therapeutique | |
| JPH04982B2 (da) | ||
| JPH0224821B2 (da) | ||
| FI67686B (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara fenetanolaminderivat | |
| ES2276547T3 (es) | Derivados de 2-(n-cianoimino)tiazolidin-4-ona. | |
| EP0248824B1 (en) | Use of cis-n-(2 aminocycloaliphatic) benzene acetamide and benzamide for the manufacture of anticonvulsants | |
| JP3559045B2 (ja) | 薬理学的活性を有する２−メルカプトベンズイミダゾール誘導体 | |
| FI63938C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara substituerade 2,3-alkylenbis(oxi)bensamider | |
| FR2493702A1 (fr) | Compositions antivirales contenant des derives d'acide aminosulfonylhalogenobenzoique | |
| ES2519441T3 (es) | Compuestos para tratar la impotencia | |
| JPH02268172A (ja) | 新規なベンズオキサゾリノン誘導体 | |
| JPH04360881A (ja) | 新規のベンゾセレナゾリノン化合物、これらを調製するプロセスおよびそれらを含む薬剤組成物 | |
| PL97347B1 (pl) | Sposob wytwarzania nowych 2-fenylohydrazyno-tiazolin lub-tiazyn | |
| FR2465733A1 (fr) | Nouveaux derives imidazolylethoxymethyliques de 1,3-dioxoloquinoleines utiles notamment comme medicaments antibacteriens et antifongiques, leur procede de preparation et compositions therapeutiques et formes pharmaceutiques les contenant | |
| JPS6117832B2 (da) | ||
| EP0334674B1 (en) | Use of isoxazolinones as cerebro-active drugs | |
| FI60863C (fi) | Foerfarande foer framstaellning av nya bentshydryloxialkylaminderivat med foerlaengd antihistamineffekt | |
| EP0045473B1 (en) | A pharmaceutical composition containing a benzofuran-carboxamide derivative as the active ingredient | |
| JPS5935387B2 (ja) | ３−アミノ−２−ヒドロキシプロパンのジ−置換フエノ−ルエ−テル類、その製法ならびに医薬用途 | |
| US3457354A (en) | Treatment of hypertension with 2-hydroxy (or amino) - 4,5 - dihydroxyphenethylamine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: SOCIETE D'ETUDES SCIENTIFIQUES ET |